The first evidence that removing amyloid plaques may delay Alzheimer’s symptoms has now been published. In The Lancet Neurology on March 19, scientists led by Randall Bateman at Washington University ...
Like lecanemab before it, donanemab’s path to market has been slow and rocky. In the U.S., the antibody received Food and Drug Administration approval about nine months ago, but only a few hundred ...
12 June 2025 DOWNLOAD TO YOUR CALENDAR Online Meeting View Conference Website ...
Eight years ago, people were amazed by the first high-resolution glimpse into the core of tau fibrils extracted from the brain of a person who had had Alzheimer’s disease. Since those iconic ...
The ESBTB is the first of its kind in the UK. It is dedicated to the study of epilepsy and Sudden Death in Epilepsy (SUDEP), providing brain and other tissue samples to researchers for ethically ...